Join
Live feed
·
PRReleasevia Quantisnow
Ocugen Inc. logo

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

ByQuantisnow·Wall Street's wire, on your screen.
OCGN· Ocugen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCGN (Ocugen Inc.) and more on Quantisnow.